DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170899

The potential nephrotoxic effect of single tablet of 15 mg primaquine in G6PD deficient Hadoti region population of India

Vikash Khandelia, Pavankumar Pyarsabadi, Umashankar Nama, Saurabh Chittora, Yogesh Swami, Hemant Richariya

Abstract


Primaquine is used in prevention of relapse of plasmodium vivax and ovale. It is known to cause haemolysis induced acute kidney injury in patients with glucose-6-phosphate dehydrogenase (G-6-PD) enzyme deficiency. Primaquine is widely used in the remote areas of Hadoti region of India by many non-registered practitioners for treatment of febrile illnesses without prior testing of G-6-PD status. Due to this practice, many patients land up with the grave consequences with significant health care burden. We report 8 such cases, which were referred to our hospital, New hospital medical college, Kota, Rajasthan, India. Our study included a series of 8 cases which were referred to our hospital with significantly deranged renal function test due to use of primaquine without prior testing of G-6-PD status. Routine blood investigations including renal function tests and G-6-PD status were measured. In our study, we found that patients with febrile illness and G-6-PD deficiency developed acute kidney injury even with a single tablet of 15 mg of primaquine. The use of even a single dose of 15 mg primaquine may not be safe in population of Hadoti region of India. Hence they should not be exposed to primaquine without prior G-6-PD testing.


Keywords


AKI, G6PD, New hospital medical college Kota, Primaquine

Full Text:

PDF

References


Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5:e128.

Genton B, Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008;5:e127.

Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996;55:243-9.

Edgcomb JH, Arnold J, Yount EH, Alving AS, Eichelberger L, Jeffery GM, et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950;9:285-92.

Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, et al. High-dose primaquine regimens against relapse of plasmodium vivax malaria. Am J Trop Med Hyg. 2008;78:736-40.

Bolchoz LJ, Morrow JD, Jollow DJ, McMillan DC. Primaquine-induced hemolytic anemia: effect of 6-methoxy-8-hydroxylaminoquinoline on rat erythrocyte sulfhydryl status, membrane lipids, cytoskeletal proteins, and morphology. J Pharmacol Exp Ther. 2002;303:141-8.

Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779-89.

George JN, Sears DA, McCurdy PR, Conrad ME. Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G-6-PD deficient subjects. J Lab Clin Med. 1967;70:80-93.

Monteiro WM, Franca GP, Melo GC, Queiroz AL, Brito M, Peixoto HM, et al. Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes. Malar J. 2014;13:70.

Khoo KK. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann Trop Med Parasitol. 1981;75:591-5.

Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.

Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.

White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11:418.

Alving AS, Et AL. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bulletin of the world health organization. 1960;22:621-31.

Clyde DF, Mccarthy VC. Radical cure of chesson strain vivax malaria in man. Am J Tropical Med Hygiene. 1977;26:562-3.

Pannacciulli I, Salvidio E, Tizianello A, Parravidino G. Hemolytic effects of standard single dosages of primaquine and chloroquine on G-6-PD-deficient Caucasians. J Lab Clin Med. 1969;74:653-61.

Reeve PA, Toaliu H, Kaneko A, Hall JJ, Ganezakowski M. Acute intravascular haemolysis in Vanuata following a single dose of primaquine in individuals with glucose- 6- phosphate dehydrogenase deficiency. J Trop Med Hyg. 1992;95:349-51.

Karwacki JJ, Shanks GD, Kummalue T, Watanasook C. Primaquine induced hemolysis in a Thai soldier. Southeast Asian J Trop Med Public Health. 1989;20:555-6.

Salvidio E, Pannacciulli I, Tizianello A, Ajmar F. Nature of hemolytic crisis and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. N Engl J Med. 1967;276:1339-44.

Batu AT. Primaquine induced haemolysis in G-6-PD deficient Burmese. Transactions Royal Society Trop Med Hygiene. 1970;64:785-6.

Charoenlarp P. The course of primaquine-induced haemolysis in G-6-PD deficient Thais. J Med Asso Thailand. 1972;55:631-7.